Publications by authors named "Emmanuelle Nicolas Virelizier"

Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management.

View Article and Find Full Text PDF
Article Synopsis
  • * Out of 89 participants, the treatment achieved a complete metabolic response (CMR) in 77.5% of cases after 6 cycles, with a tolerance for side effects, as 88% completed the regimen despite a 20% rate of serious adverse events.
  • * In long-term follow-up (median 42 months), the 4-year progression-free survival rate was 50% and overall survival 69%, with factors like liver involvement and lymphopenia affecting outcomes.
View Article and Find Full Text PDF

Background: t-AML occurs after a primary malignancy treatment and retains a poor prognosis.

Aims: To determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of t-AML.

Results: A total of 112 adult patients were included in this study.

View Article and Find Full Text PDF

Low baseline NK-cell counts (NKCCs) in patients with diffuse large B-cell lymphoma (DLBCL) are associated with a poor prognosis. The REMARC phase III trial (NCT01122472) showed that lenalidomide maintenance prolonged PFS in rituximab-chemotherapy responders. We conducted a REMARC ancillary study analysing the impact of lenalidomide maintenance on the prognostic value of low NKCCs.

View Article and Find Full Text PDF

This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients. Phase I study was designed to determine the maximum tolerated dose (MTD) of BV (10 patients) and phase II evaluated the rate of complete metabolic response (CMR) after 2 cycles of BV-ICE (42 patients). There were no dose-limiting toxicities (DLT) during phase I recommending BV 1.

View Article and Find Full Text PDF
Article Synopsis
  • Doctors studied a new treatment called BV-AVD for patients with a tough type of cancer called early-stage unfavorable Hodgkin lymphoma.
  • * The study involved 170 patients who either received BV-AVD or a standard treatment called ABVD and checked how many were cancer-free after two rounds of treatment.
  • * The results showed that more patients treated with BV-AVD were cancer-free compared to those who had ABVD.
View Article and Find Full Text PDF

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-line rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years with an aaIPI (age-adjusted International Prognostic Index) score ≥1 (registered as NCT00144755). We implemented a prospective long-term follow-up program at the end of this trial. The primary endpoints were progression-free survival (PFS) and overall survival (OS).

View Article and Find Full Text PDF
Article Synopsis
  • Stage IIB Hodgkin lymphoma (HL) patients with certain risk factors have a poor prognosis and are treated either as limited or advanced stage, with differing clinical trials comparing these treatment approaches.
  • A study involving 148 patients showed that baseline total metabolic tumor volume (TMTV) and responses after two cycles of chemotherapy significantly influenced progression-free survival rates, with a median follow-up of 4.1 years showing PFS rates around 88%.
  • The findings suggest that both upfront ABVD plus radiation therapy and upfront escBEACOPP without radiotherapy yield similar outcomes in these high-risk patients, while TMTV can effectively stratify their risk at baseline.
View Article and Find Full Text PDF
Article Synopsis
  • High-dose melphalan (HDM) combined with bortezomib (Bor-HDM) was tested in a phase 3 trial for patients with multiple myeloma to see if it was more effective than HDM alone.* -
  • The trial included 300 patients, and results showed no significant differences in complete response rates or minimum residual disease rates between the two treatment groups.* -
  • Although progression-free survival was slightly better in the Bor-HDM group (34.0 months) compared to HDM (29.6 months), the overall survival rates and serious adverse events were similar, indicating Bor-HDM did not provide a clear advantage.*
View Article and Find Full Text PDF

Purpose: The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) provides similar progression-free survival (PFS) and overall survival (OS) and reduces early toxicity compared with a nonmonitored standard treatment. Here, we report, with a prolonged follow-up, the final study results.

View Article and Find Full Text PDF

Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL.

View Article and Find Full Text PDF

Bispecific therapies targeting CD3, so-called T-cell engagers (TCE), belong to the new spectrum of anti-tumor immunotherapies stimulating T-lymphocytes. TCE are unique constructs targeting the MHC-independent CD3 epsilon subunit (CD3e) and a tumor antigen. To date, only blinatumomab have reached market agreements in lymphoid malignancies with constructs targeting CD3exCD19.

View Article and Find Full Text PDF

We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m) in combination with etoposide (300 mg/m) and ifosfamide (1500 mg/m) at 2, 3, or 4-week intervals. Median age was 79 years (range, 64-92). The median number of previous line was 1 (range 1-8).

View Article and Find Full Text PDF

Background: No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors.

Methods: Health care costs were measured from the payer perspective.

View Article and Find Full Text PDF

Cholesterol granuloma (CG) is a foreign body-type granuloma that forms in response to cholesterol crystals. Its etiology and pathogenesis are unclear. 18F-FDG is not a tumor-specific agent.

View Article and Find Full Text PDF

Introduction: Older adults with cancer suffer from the combined effects of ageing, cancer disease and treatment side effects. The main treatment for patients with haematological malignancies is chemotherapy, associated with significant toxicities. Chemotherapy can alter patients' physical function and quality of life which are often already diminished in older patients due to ageing and comorbidities.

View Article and Find Full Text PDF

Objectives: We present here data on Gram-negative rods bacteremia (GNRB) rates, risk factors and associated mortality.

Methods: Data on GNRB episodes were prospectively collected in 65 allo-/67 auto-HSCT centers in 24 countries (Europe, Asia, Australia). In patients with and without GNRB, we compared: demography, underlying disease, HSCT-related data, center` fluoroquinolone prophylaxis (FQP) policy and accreditation status, and involvement of infection control team (ICT).

View Article and Find Full Text PDF

Background: The role of high-dose chemotherapy with autologous stem cell transplantation (ASCT) in the treatment of soft-tissue sarcoma (STS) remains an unsettled issue. Prospective clinical trials failed to prove a benefit of the procedure but were limited by small and heterogeneous patient cohorts. Thus, it is unknown if ASCT may be a valuable treatment option in specific patient subgroups.

View Article and Find Full Text PDF
Article Synopsis
  • Two FDA-approved CAR T cell therapies, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), were studied in a retrospective analysis of 70 patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) to evaluate their usage, effectiveness, and safety.
  • The study found overall response rates (ORRs) of 63% at 1 month and 45% at 3 months, with median progression-free survival (PFS) of 3.0 months and overall survival (OS) of 11.8 months, indicating significant but variable effectiveness across patients.
  • Common side effects included cytokine release syndrome (CR
View Article and Find Full Text PDF

Purpose: Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents and dexamethasone. We prospectively compared the efficacy and safety of MDex and MDex with the addition of bortezomib (BMDex).

View Article and Find Full Text PDF
Article Synopsis
  • The study explored survival factors in cancer patients suspected of having COVID-19, highlighting that these patients face a significantly high risk of death.
  • Out of 302 cancer patients, 18.2% tested positive for SARS-CoV-2 via RT-PCR, with older patients and those with respiratory symptoms being more prevalent in this group.
  • The death rates at a median follow-up of 25 days were 21% for RT-PCR-positive and 10% for RT-PCR-negative patients, with risk factors for death including male gender, poor performance status, and presence of respiratory symptoms, but the viral detection did not correlate with increased mortality.
View Article and Find Full Text PDF